Literature DB >> 19253145

Diagnostic imaging of experimental invasive pulmonary aspergillosis.

Thomas J Walsh1, Vidmantas Petraitis, Ruta Petraitiene, Jeffrey Solomon, John D Bacher, Lora Greene, Margaret Cotton, Andreas Groll, Emmanuel Roilides, Nilo Avila, Vasilios Pyrgos, Shmuel Shoham.   

Abstract

Pulmonary infiltrates in neutropenic hosts with invasive aspergillosis are caused by organism-mediated tissue injury, vascular invasion, and hemorrhagic infarction. Ultrafast computed tomography (UFCT) scanning reproducibly measures these lesions in experimental invasive pulmonary aspergillosis in persistently neutropenic rabbits. The pulmonary lesion score from UFCT scanning is a useful outcome variable for measuring differences in efficacy of antifungal compounds alone and in combination, as well as the virulence of different strains and species of Aspergillus. Several studies demonstrate that the course of pulmonary lesions treated with amphotericin B, lipid formulations of amphotericin B, triazoles, echinocandins, and combination therapy measured by serial UFCT scans correlate with those measured by survival, histopathological resolution of lesions, microbiological clearance of Aspergillus fumigatus, and resolution of galactomannan index. We further developed a multidimensional volumetric imaging (MDVI) method for analysis of the volume of pulmonary infiltrates over time in response to antifungal therapy. Volumetric data by MDVI correlate with UFCT pulmonary lesion scores and validated biological endpoints. A recent pilot clinical study demonstrated the applicability of MDVI to human pulmonary fungal infections. MDVI also improves objectivity of radiological assessment of therapeutic response to antifungal therapy and merits more extensive evaluation in patients with invasive aspergillosis, as well as other fungal and bacterial pneumonias.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19253145      PMCID: PMC7295091          DOI: 10.1080/13693780802665879

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  13 in total

1.  Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Alia A Sarafandi; Amy M Kelaher; Caron A Lyman; Heather E Casler; Tin Sein; Andreas H Groll; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  J Infect Dis       Date:  2003-06-04       Impact factor: 5.226

2.  Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Emmanuel Roilides; David E Kleiner; R Schaufele; Maureen Roden; Susan Harrington; Luqman Dad; Brahm Segal; Thomas J Walsh
Journal:  Am J Clin Pathol       Date:  2007-03       Impact factor: 2.493

3.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Multidimensional volumetric imaging of pulmonary infiltrates for measuring therapeutic response to antifungal therapy in experimental invasive pulmonary aspergillosis.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Jeffrey Solomon; Amy M Kelaher; Heidi A Murray; Christine Mya-San; Avi K Bhandary; Tin Sein; Nilo A Avila; Algidas Basevicius; John Bacher; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

Authors:  P Francis; J W Lee; A Hoffman; J Peter; A Francesconi; J Bacher; J Shelhamer; P A Pizzo; T J Walsh
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226

6.  Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

Authors:  R Petraitiene; V Petraitis; A H Groll; T Sein; S Piscitelli; M Candelario; A Field-Ridley; N Avila; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

Authors:  Thomas J Walsh; Vidmantas Petraitis; Ruta Petraitiene; Aida Field-Ridley; Deanna Sutton; Mahmoud Ghannoum; Tin Sein; Robert Schaufele; Joanne Peter; John Bacher; Heather Casler; Derek Armstrong; Anna Espinel-Ingroff; Michael G Rinaldi; Caron A Lyman
Journal:  J Infect Dis       Date:  2003-07-09       Impact factor: 5.226

8.  Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression.

Authors:  J Berenguer; M C Allende; J W Lee; K Garrett; C Lyman; N M Ali; J Bacher; P A Pizzo; T J Walsh
Journal:  Am J Respir Crit Care Med       Date:  1995-09       Impact factor: 21.405

9.  Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Caron A Lyman; Andreas H Groll; Diana Mickiene; Joanne Peter; John Bacher; Kristin Roussillon; Melissa Hemmings; Derrek Armstrong; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy.

Authors:  T J Walsh; K Garrett; E Feurerstein; M Girton; M Allende; J Bacher; A Francesconi; R Schaufele; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

View more
  3 in total

1.  Longitudinal, in vivo assessment of invasive pulmonary aspergillosis in mice by computed tomography and magnetic resonance imaging.

Authors:  Jennifer Poelmans; Amy Hillen; Liesbeth Vanherp; Kristof Govaerts; Johan Maertens; Tom Dresselaers; Uwe Himmelreich; Katrien Lagrou; Greetje Vande Velde
Journal:  Lab Invest       Date:  2016-03-28       Impact factor: 5.662

Review 2.  Antifungal pharmacokinetics and pharmacodynamics.

Authors:  Alexander J Lepak; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

3.  Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis.

Authors:  Thomas J Walsh; Mark C Wissel; Kevin J Grantham; Ruta Petraitiene; Vidmantas Petraitis; Miki Kasai; Andrea Francesconi; Margaret P Cotton; Johanna E Hughes; Lora Greene; John D Bacher; Pradip Manna; Martin Salomoni; Steven B Kleiboeker; Sushruth K Reddy
Journal:  J Clin Microbiol       Date:  2011-10-05       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.